“…protein tyrosine kinase (PTK) inhibitor and has specificity for five kinases/kinase families (BCRABL, c-SRc, c-KIT, PDGFβ receptor, and EPHA2). In vitro, in vivo, and early clinical trials demonstrate potent antiproliferative activity in a wide spectrum of cancer cell lines/types, and patients with chronic myelogenous leukemia (CML) and solid tumor patients [11][12][13]. Dasatinib has also shown potent inhibition of vascular endothelial growth factor-and basic fibroblast growth factordriven proliferation of human umbilical vein endothelial cells, with IC50 values of 43 and 248 nM, respectively.…”